Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our alumnus Simon Mendelsohn (cohort 2015-2016) co-authored the publication of the results from a study into a blood-based RNA biomarker which tested diagnostic and prognostic performance for TB and the efficacy of TB preventive therapy for biomarker-positive individuals

A blood biomarker of tuberculosis discriminated between people at high risk for tuberculosis and those who remained healthy, but an effective preventive therapy for people at risk remains elusive.

The Lancet Infectious Diseases journal reports the findings of a study of a host blood signature of TB that differentiated between people who had or would develop active TB and those who remained healthy, and investigated in parallel the effect of giving TB preventive therapy based on a positive signature result.

 

Read the South African Tuberculosis Vaccine Initiative media release.